کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
8738507 | 1591728 | 2018 | 24 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Evaluation of linezolid or trimethoprim/sulfamethoxazole in combination with rifampicin as alternative oral treatments based on an in vitro pharmacodynamic model of staphylococcal biofilm
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
موضوعات مرتبط
علوم زیستی و بیوفناوری
ایمنی شناسی و میکروب شناسی
میکروبیولوژی و بیوتکنولوژی کاربردی
پیش نمایش صفحه اول مقاله

چکیده انگلیسی
Combinations of linezolid (LZD) or trimethoprim/sulfamethoxazole (SXT) plus rifampicin (RIF) are alternative oral treatments for staphylococcal prosthetic joint infections (PJIs) when fluoroquinolones are not possible to use, but there is limited evidence regarding their activity. This study evaluated the efficacy of LZD and SXT, alone and in combination with RIF, against Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic biofilm model. Using the CDC Biofilm Reactor® system, simulated regimens of LZD (600âmg every 12âh), SXT (160/800âmg every 8âh) and levofloxacin (LVX) (750âmg/day), alone and in combination with RIF (600âmg/day), were evaluated against one methicillin-susceptible S. aureus (MSSA) and one methicillin-resistant S. aureus (MRSA) strain. Antibiotic efficacy was evaluated by the decrease in planktonic bacterial counts from medium and biofilm-embedded bacteria from coupons over 56âh. Resistant strains were screened. In both strains, SXT alone was ineffective and LZD presented low activity, but no resistance emerged. Combinations with RIF significantly increased the antibiofilm efficacy against MSSA (Îlog CFU/mL 56h-0h: SXTâ+âRIF, â2.9 and LZDâ+âRIF, â3.1), but RIF-resistant strains appeared with SXTâ+âRIF. Against MRSA, LZDâ+âRIF (â3.1) protected against the emergence of resistance and was more effective than SXTâ+âRIF (â0.6; Pâ<0.05), in which RIF-resistant strains were again detected. LVXâ+âRIF confirmed its high efficacy against biofilm-embedded bacteria, this being the most effective therapy (â5.1 against MSSA). The emergence of RIF-resistant strains with SXTâ+âRIF poses serious concerns for its use in clinical practice. Interestingly, LZDâ+âRIF appears to be an appropriate alternative for PJI caused by LVX-resistant S. aureus.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: International Journal of Antimicrobial Agents - Volume 51, Issue 6, June 2018, Pages 854-861
Journal: International Journal of Antimicrobial Agents - Volume 51, Issue 6, June 2018, Pages 854-861
نویسندگان
Cristina El Haj, Oscar Murillo, Alba Ribera, Nuria Lloberas, Joan Gómez-Junyent, Fe Tubau, Pere Fontova, Carme Cabellos, Javier Ariza,